Primmune Therapeutics is Drug Discovery in United States that focus on developer business. Founded in 2017. They cover business area such as developer, an orally administer toll-like receptor agonist, innate immunity, cancer immunotherapy, cytokine, chemokine, up-regulate general cellular response, natural killer cell activation, medical practitioner, all metastatic disease, B-cell proliferation.
2017
( 7 years old in 2024 )
Developer
-
JLABS San Diego
3210 Merryfield Row
San Diego, CA 92121
United States
Private
developeran orally administer toll-like receptor agonistinnate immunitycancer immunotherapycytokinechemokineup-regulate general cellular responsenatural killer cell activationmedical practitionerall metastatic diseaseB-cell proliferation
* We use standard office opening hours in near Primmune Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Primmune Therapeutics is Drug Discovery business from United States that founded in 2017 (7 years old in 2024), Primmune Therapeutics business is focusing on Developer.
Primmune Therapeutics headquarter office and corporate office address is located in JLABS San Diego 3210 Merryfield Row San Diego, CA 92121 United States.
Primmune Therapeutics was founded in United States.
In 2024, Primmune Therapeutics is currently focus on developer sector.
Above is snippet of Google Trends for "developer" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Primmune Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
